Nocca D, Aggarwal R, Mathieu A, Blanc P M, Denève E, Salsano V, Figueira G, Sanders G, Domergue J, Millat B, Fabre P R
Digestive Surgery Center, Saint-Eloi Hospital, University Hospital Complex-Montpellier, Montpellier, France.
Surg Endosc. 2007 Aug;21(8):1373-6. doi: 10.1007/s00464-007-9218-8. Epub 2007 Mar 14.
Nowadays, laparoscopic adrenalectomy is the "gold standard" procedure for the treatment of benign lesions. However, the situation is not so clearcut when the issue is laparoscopic excision of malignant adrenal tumors. We present our results of laparoscopic adrenalectomy for treating malignant tumors over the past decade.
Between October 1995 and June 2004, 131 consecutive laparoscopic adrenalectomies were performed on 120 patients (11 synchronous bilateral procedures). All patients underwent a standardized investigation protocol during their workup for surgery.
There were only two conversions to laparotomy (1.6%). Complications that occurred during the procedure were limited to six patients (5%). Postoperative 30-days mortality was nil. Postoperative complications occurred in five patients (4.7%) during the first 30 days of recovery. The median hospital stay for all patients was 2.5 days (range = 2-10 days). Twelve patients (9%) had a malignant tumor: nine corticoadrenalomas, one pleomorphic sarcoma, one metastatic deposit from a previously excised colonic cancer, and one malignant pheochromocytoma. At mean followup of 34 months, mean survival time was 42.3 months for corticoadrenalomas that had undergone laparoscopy versus 29.7 months for those who had had a laparotomy. Five of the nine patients are alive and well at a mean of 37 months following surgery. One patient developed pulmonary metastases one year postsurgery; they were responsive to mitotane. Five years later, the same patient had a reoperation for an intra-abdominal retrogastric recurrence of her tumor and continues to do well. Another patient developed pulmonary metastases 22 months following adrenalectomy. Two patients died of metastatic intra-abdominal disease 20 and 7 months postsurgery.
When laparoscopic surgery is to used for cancer treatment, caution is the rule to maintain the primary objective of securing a survival rate at least as high as that for open surgery, without increased risk of recurrence. Considering the results presented within this study, it seems that the laparoscopic removal of a corticoadrenaloma should not worsen the prognosis, provided the surgeon respects the primary rules of oncologic resectional surgery. Any surgical conditions that would preclude the strict application of these criteria are contraindications to a laparoscopic procedure.
如今,腹腔镜肾上腺切除术是治疗良性病变的“金标准”术式。然而,当涉及腹腔镜切除恶性肾上腺肿瘤时,情况就不那么明确了。我们展示了过去十年间腹腔镜肾上腺切除术治疗恶性肿瘤的结果。
1995年10月至2004年6月,对120例患者(其中11例为同期双侧手术)连续实施了131例腹腔镜肾上腺切除术。所有患者在术前检查期间均接受了标准化的检查方案。
仅2例转为开腹手术(1.6%)。术中发生的并发症仅限于6例患者(5%)。术后30天死亡率为零。术后恢复的前30天内,5例患者(4.7%)出现并发症。所有患者的中位住院时间为2.5天(范围 = 2 - 10天)。12例患者(9%)患有恶性肿瘤:9例肾上腺皮质腺瘤、1例多形性肉瘤、1例来自先前切除的结肠癌的转移灶以及1例恶性嗜铬细胞瘤。平均随访34个月时,接受腹腔镜手术的肾上腺皮质腺瘤患者的平均生存时间为42.3个月,而接受开腹手术的患者为29.7个月。9例患者中有5例在术后平均37个月时存活且状况良好。1例患者术后1年出现肺转移;对米托坦有反应。5年后,该患者因肿瘤腹腔内胃后复发再次手术,目前情况仍然良好。另1例患者在肾上腺切除术后22个月出现肺转移。2例患者分别在术后20个月和7个月死于腹腔内转移性疾病。
当使用腹腔镜手术治疗癌症时,谨慎是原则,要确保生存率至少与开腹手术一样高这一主要目标,同时不增加复发风险。考虑到本研究呈现的结果,似乎只要外科医生遵循肿瘤切除手术的基本规则,腹腔镜切除肾上腺皮质腺瘤不应使预后变差。任何妨碍严格应用这些标准的手术情况都是腹腔镜手术的禁忌证。